Gil P, et al. - Experts assessed the impact of the vitreoretinal interface on the outcomes of different ranibizumab regimens for exudative age-related macular degeneration. For 12 months, patients were treated with ranibizumab according to 3 different regimens: pro-re-nata (PRN), treat and extend (T&E), and monthly. Researchers noted the regimen-dependent negative impact of the absence of posterior vitreous detachment (PVD), similar outcomes were seen among PVD patients with monthly dosing. PRN ought to be avoided in the absence of PVD (group ON), and T&E could be an alternative.